Exercise of employee share options, mandatory notification of trade and resolution to increase share capital
Oslo (Norway), 20 February 2019 – Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the “Company”). Options exercised and mandatory notification of trade on 20 February 2019 Participants in the Company’s share option program have on 20 February 2019 exercised a total […]
Fourth quarter and preliminary 2018 results
Oslo (Norway), 13 February 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim fourth quarter and preliminary 2018 result. Please find enclosed the report and presentation. Solid performance through 2018, moving towards initiation of the pivotal “RELEASE” study The fully underwritten rights issue of NOK 360 million completed in […]
Oslo, Norway, 05 February 2019 – PCI Biotech invites to a presentation of the company’s fourth quarter and preliminary 2018 report on Wednesday 13 February 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday February 13, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, […]